CRO Outperforms CPO in August: Is a Rally in Pharmaceutical Stocks Next After the Optical Module Surge?

① The semi-annual report indicates that the operating performance and order backlog of multiple CRO companies have resumed rapid growth, driven by a robust recovery in client demand; ② In Q2, fund allocations to the pharmaceutical sector overall dropped to historic lows, yet innovative drugs and CROs emerged as the primary areas for contrarian accumulation by capital at market bottoms; ③ The CDMO sub-sector has entered a critical period for new contract signings and the volume ramp-up of major overseas products.

cls.cn08:48

Spring for Non-Tech Sectors? Pharmaceutical Sector Surpasses Semiconductors in Research Interest

① Last week, the pharmaceutical and biotechnology sector received 104 visits from public mutual fund institutions for research purposes, ranking first among all SW1 sectors, with nearly double the number of visits compared to the second-ranked sector. ② The sector’s valuation remains at a relatively low level and offers ample growth potential, making it attractive for portfolio allocation and prompting multiple public mutual fund institutions to actively conduct research. ③ The sector may face risks of volatility and divergence, and investors should avoid blind investment.

cls.cnAug 11 12:08

Repurchase announcements disclosed in a concentrated manner reveal the latest portfolio adjustments by a group of star fund managers.

① Since July, publicly offered funds have shown divergent positioning adjustments in hard-tech stocks such as semiconductors and electronic chemicals; ② Yang Zongchang, who successfully 'timed the market peak,' has newly entered the top ten circulating shareholders of Sany Heavy Industry through his fund products; ③ Some fund managers have reduced holdings in upstream mining and smelting and midstream manufacturing segments of the new energy sector, while newly entering the top ten circulating shareholders of power grid equipment companies; ④ According to current disclosures, prominent fund managers including Ge Lan, Zhang Kun, and Huang Xingliang have all reduced their positions in pharmaceutical stocks.

cls.cnAug 9 16:04

Innovative pharmaceuticals and the CDMO sector attract intensive institutional research visits, with ESMO-disclosed data and overseas business development progress drawing attention.

① During this week (August 3 to August 9), a total of 57 A-share companies received institutional investor visits. ② Among them, BeiGene received the highest number of visits, hosting 207 institutions. ③ Zelgen Biopharmaceuticals and Zhejiang Jiuzhou Pharmaceutical ranked among the top ten listed companies by number of visiting institutions, with 97 and 77 institutions respectively.

cls.cnAug 9 13:19

Riding the Tide, Staying True to Purpose: Decoding the Era’s Answer to the Rise of Domestic Pharmaceutical Companies

① Clinical needs have become the central focus of pharmaceutical innovation in China, with both policy makers and industry players placing increasing emphasis on the real-world clinical value of drugs; ② Chinese pharmaceutical companies are pursuing multiple pathways for international expansion—ranging from licensing out overseas commercialization rights for upfront cash proceeds to independently building global commercial infrastructures—leading the sector toward a dual-track approach combining 'building their own ships' and 'borrowing others’ ships.'

cls.cnAug 8 17:10

Express News | Most Hong Kong-listed innovative drug stocks rose, with Zai Lab surging over 14%, Wuxi Bio gaining more than 6%, Wuxi Apptec rising nearly 6%, and Ascletis Pharma and Confo Therapeutics each climbing over 4%.

BreakingsAug 7 11:04